Last reviewed · How we verify
NCT03065543: TERCETZabrze
Hyperlipidemia Therapy TERCET Zabrze Registry
trial in Hyperlipidemias in 25,000 participants. Status unknown.
31 December 2016
Quick facts
| Lead sponsor | Silesian Centre for Heart Diseases |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 25,000 |
| Start date | 1 January 2006 |
| Primary completion | 31 December 2016 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Poland |
Conditions studied
- Hyperlipidemias — all drugs for Hyperlipidemias →
- Secondary Prevention — all drugs for Secondary Prevention →
Sponsor
Silesian Centre for Heart Diseases — full company profile →
Who can join
18 and older, any sex, with Hyperlipidemias or Secondary Prevention. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A study conducted to evaluate the efficacy of lipid-lowering therapy in patients with high and very high risk treated by interventional cardiology. Study endpoints: 1. Achievement of the target LDL-C at 1-year follow-up LDL-C \<70 mg / dl in the group of very high-risk and LDL-C \<100 mg / dL in high-risk patients 2. Assessment of the lipid profile of the severity of coronary artery disease in patients undergoing invasive diagnosis of coronary artery disease 3. Evaluation of trends in the treatment of lipid-lowering in patients in different years
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry.
Dyrbuś K, Gąsior M, Desperak P, Trzeciak P, et al · · 2021 · cited 21× · PMID 34418681 · DOI 10.1016/j.atherosclerosis.2021.08.024 -
Evaluation of dyslipidaemia and the impact of hypolipidemic therapy on prognosis in high and very high risk patients through the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) Registry.
Dyrbuś K, Osadnik T, Desperak P, Desperak A, et al · · 2018 · cited 18× · PMID 29258913 · DOI 10.1016/j.phrs.2017.12.015
Verify or expand the search:
- PubMed search for NCT03065543
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hyperlipidemias
Currently open trials in the same condition.
- NCT06903897 — Social Needs Screening and Chronic Diseases Study (WE CARE) · NA · recruiting
- NCT06049420 — Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients · NA · recruiting
- NCT06461273 — Food is Medicine vs Lifestyle Medicine For Cardiovascular Kidney Metabolic (CKM) Syndrome · NA · active not recruiting
- NCT06094491 — Virtual Diabetes Group Visits Across Health Systems · Phase 2 · active not recruiting
- NCT06055036 — Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention · NA · recruiting
Other Silesian Centre for Heart Diseases trials
Trials by the same sponsor.
- NCT04453748 — The Assessment of the Prevalence, Clinical Course and Treatment of COVID-19 Complications · unknown
- NCT04450745 — Physical Exercise in Normobaric Hypoxia and Normoxia in Type 1 Diabetic Patients · NA · completed
- NCT03588962 — Metal Allergy In-Stent Restenosis Study · NA · unknown
- NCT03654859 — Silesian Registry of Out-of-Hospital Cardiac Arrests · unknown
- NCT03781492 — Stable Angina Management and Treatment · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03065543 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Silesian Centre for Heart Diseases
- Last refreshed: 28 February 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03065543.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing